6,906 Shares in AbbVie Inc. $ABBV Bought by Fiduciary Financial Advisors

Key Points

• Fiduciary Financial Advisors acquired 6,906 AbbVie shares in the second quarter, valued at approximately $1.75 million. Institutional investors collectively own 70.23% of AbbVie’s outstanding stock.
• AbbVie reported positive Phase 3 results for etentamig in multiple myeloma and completed its approximately $10.9 billion acquisition of Apogee Therapeutics, strengthening its oncology and immunology pipelines while creating near-term earnings dilution.
• Analysts maintain a generally bullish outlook, with AbbVie holding a “Moderate Buy” consensus rating and an average price target of $275.95. Shares recently opened at $260.69, while the company reaffirmed 2026 adjusted EPS guidance of $13.87 to $14.07.

Fiduciary Financial Advisors acquired a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,906 shares of the company's stock, valued at approximately $1,754,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie in the fourth quarter worth $28,000. Imprint Wealth LLC increased its stake in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after purchasing an additional 45 shares during the period. Burk Holdings LLC bought a new stake in shares of AbbVie during the second quarter valued at about $30,000. Legacy Wealth Managment LLC ID grew its position in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock valued at $31,000 after buying an additional 73 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new position in AbbVie during the 4th quarter valued at about $31,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers positive Phase 3 results. AbbVie said its CERVINO trial met both primary endpoints in relapsed/refractory multiple myeloma. The treatment produced a 74% objective response rate and reduced the risk of disease progression or death by 60% versus standard therapies. The results support a potential new oncology growth driver and may allow AbbVie to compete for share in the increasingly competitive multiple myeloma market. AbbVie CERVINO Phase 3 results
• Positive Sentiment: Apogee expands AbbVie’s immunology pipeline. AbbVie completed its approximately $10.9 billion acquisition of Apogee Therapeutics, adding late-stage zumilokibart for atopic dermatitis and additional programs targeting asthma and other inflammatory diseases. The deal strengthens AbbVie’s post-Humira growth prospects and diversifies its pipeline. AbbVie completes Apogee acquisition
• Neutral Sentiment: Full-year earnings guidance was reaffirmed. AbbVie maintained adjusted 2026 EPS guidance of $13.87 to $14.07 and third-quarter guidance of $3.84 to $3.88. The range is broadly consistent with expectations, but its midpoint is slightly below the current consensus estimate of $14.02, limiting the immediate upside reaction.
• Negative Sentiment: Acquisition costs create near-term pressure. The Apogee transaction is expected to dilute earnings initially and become accretive only later, reportedly around 2032. Investors may therefore focus on the substantial cash commitment and the long wait before financial benefits fully materialize. AbbVie Apogee acquisition analysis

Insider Transactions at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ABBV shares. HSBC reaffirmed a "buy" rating and issued a $300.00 price objective on shares of AbbVie in a research note on Monday, July 6th. Wells Fargo & Company lifted their target price on shares of AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a research note on Monday, August 17th. Citigroup increased their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 15th. Evercore set a $235.00 price target on AbbVie in a research report on Friday, May 15th. Finally, Bank of America upped their target price on AbbVie from $234.00 to $276.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat.com, AbbVie presently has a consensus rating of "Moderate Buy" and an average price target of $275.95.

AbbVie Price Performance

Shares of AbbVie stock opened at $260.69 on Friday. The firm has a market capitalization of $460.58 billion, a PE ratio of 73.64, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The company's fifty day moving average price is $254.57 and its two-hundred day moving average price is $229.87.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter last year, the business posted $2.97 earnings per share. The company's revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie's dividend payout ratio is presently 195.48%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source